PD-L1, an immune checkpoint protein, is known for its role in cancer cells to evade the immune response. By binding to PD-1 on T cells, it effectively inhibits T cell proliferation and cytokine production, creating a dampened immune response. On the other hand, IL-8 is a chemokine associated with tumor progression, which attracts immune cells to the tumor site but paradoxically contributes to an immune suppressive microenvironment. The ability of BP2402 to simultaneously engage both pathways signifies a paradigm shift in therapeutic strategies for TNBC, where conventional monotherapies have often fallen short.

The preclinical studies conducted by the team demonstrated that BP2402 could markedly enhance the infiltration of cytotoxic T cells into the tumor microenvironment. This infiltration is crucial, as on-site T cells can mount a more potent and localized attack against tumor cells. The enhanced antitumor immune response observed results from the bispecific antibody’s ability to block the PD-1/PD-L1 interactions while simultaneously modulating IL-8 signaling, which orchestrates the tumor’s immune infiltrate. These results present an empowering narrative that bi-specific antibodies like BP2402 could galvanize a more robust immune response, steering the body’s defenses toward a more aggressive stance against cancer.

Additionally, researchers noted that the dual inhibition not only improved T cell activity but also reduced the overall levels of IL-8 in the tumor microenvironment. By lowering the levels of this chemokine, BP2402 holds the potential to eliminate the detrimental effects associated with IL-8’s immunosuppressive role. This could lead to an environment where T cells can function more effectively, unencumbered by the cellular signals that typically lead to their exhaustion. The balance between promoting T cell activities and mitigating immunosuppressive signals is critical in cancer therapy, and BP2402 appears to perform this delicate dance with exceptional finesse.

The encouraging findings from the TNBC mouse model indicate that BP2402 not only induces a noteworthy tumor regression but also significantly alters the inflammatory signaling pathways at play. In tumors treated with BP2402, a marked shift towards a pro-inflammatory environment was observed. This change was evidenced by increased production of various cytokines that foster robust immune responses. Such alterations in the inflammatory landscape could indicate a reprogramming of the tumor’s signaling networks, redirecting them towards an anti-tumorigenic profile.

The implications of these findings are vast. Given that TNBC is particularly known for its aggressiveness and lack of targeted therapy options, the advent of a bispecific antibody like BP2402 could herald a new chapter in the treatment of this subtype. It not only provides a dual mechanism of action against tumor escape strategies but also opens up avenues for potential combination therapies with existing standard-of-care agents, ultimately leading to improved outcomes for patients grappling with this disease.

Expanding the breadth of this research, the authors also highlighted that the safety profile of BP2402 was favorable, with no significant adverse effects reported in the treated mice. This data is vital when considering the translation of these findings into clinical settings. A novel therapy’s launch into human clinical trials hinges not just on its efficacy but also on its tolerability. The favorable safety profile of BP2402 sets the stage for future human studies, indicating that it could be a viable addition to the therapeutic arsenal in the fight against TNBC.

As ongoing research continues to validate these preclinical results, scientists are urged to explore the mechanistic pathways further. Understanding how BP2402 modifies the tumor microenvironment at a molecular level could provide crucial insights into further enhancing its efficacy. Potential resistance mechanisms to bispecific antibodies deserve particular attention, ensuring that the therapeutic potency of BP2402 can be maximized in patient populations that may exhibit resistance to monotherapies.

Moreover, the advent of this research aligns with the broader trend of personalized medicine in oncology, whereby treatment is increasingly tailored to the specific characteristics of both the tumor and the patient. The integration of biomarkers that can predict responses to BP2402 could enhance treatment precision, ensuring that patients most likely to benefit from such bispecific therapies are identified beforehand, ultimately optimizing therapeutic choices.

In conclusion, the study conducted by Song et al. surrounding the innovative bispecific antibody BP2402 illustrates a promising frontier in the fight against triple-negative breast cancer. By targeting both PD-L1 and IL-8, the research team is unveiling a potential that fundamentally alters therapeutic interventions and immune engagement strategies. The implications of this breakthrough are vast, offering hope to patients and paving the way for more effective treatment measures that could transform outcomes in the realm of oncology. As the medical community eagerly anticipates the transition of BP2402 from the laboratory bench to the clinical setting, the future may indeed be brighter for those affected by TNBC, as this novel therapeutic option emerges with the potential to shift the current paradigm in cancer treatment.

Subject of Research: Bispecific antibody targeting PD-L1 and IL-8 in triple-negative breast cancer.

Article Title: A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model.

Article References:

Song, L., Tang, S., Pi, X. et al. A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model.
J Transl Med 23, 1056 (2025). https://doi.org/10.1186/s12967-025-07105-x

Image Credits: AI Generated

DOI:

Keywords: Bispecific antibody, PD-L1, IL-8, triple-negative breast cancer, immunotherapy, tumor microenvironment, T cells, cytokines, safety profile, personalized medicine.

The PALOMA-2 trial, particularly its fully enrolled Cohort 5, evaluated the efficacy and safety of the Q4W (every four weeks) subcutaneous amivantamab in combination with lazertinib as a frontline therapeutic strategy for treatment-naïve patients diagnosed with EGFR Ex19del or L858R mutated advanced NSCLC. Amivantamab, a bispecific antibody targeting both EGFR and MET receptors, is designed to inhibit key proliferative and survival signaling pathways in tumor cells displaying these specific genetic alterations. Lazertinib, a potent third-generation EGFR tyrosine kinase inhibitor (TKI), complements this mechanism by selectively targeting mutant EGFR, thereby enhancing the therapeutic impact.

Among the 77 patients enrolled in the study, the median age was 63 years, reflecting a representative patient population, with demographic diversity including 68% female participants and 62% of Asian descent. Notably, 43% of patients presented with brain metastases at screening, emphasizing the real-world complexity and aggressiveness of EGFR mutation-positive NSCLC that necessitates effective systemic therapies capable of penetrating central nervous system compartments.

The dosing schedule analyzed in the trial revealed an impressive objective response rate (ORR) of 82% as assessed by investigators, which was corroborated by independent central review (ICR) confirming an ORR of 87%. These figures signify a substantial anti-cancer effect rarely matched in this heavily studied patient subgroup. Furthermore, the confirmed ORR remained high at 79% by investigator assessment and 83% by ICR. Median time to response was rapid as well, occurring at 8.1 weeks, highlighting the regimen’s ability to induce swift tumor regression.

Importantly, the median duration of response, progression-free survival (PFS), and overall survival metrics were not yet reached at the 6.5-month follow-up mark, suggesting durable benefits that warrant longer observation. The durability of response, coupled with high initial efficacy, reinforces the potential for this regimen to become a new standard of care option that balances therapeutic potency with quality of life considerations.

Safety data from the study underscore the regimen’s favorable tolerability profile. Administration-related reactions (ARRs), a common issue with antibody therapies, were observed in only 12% of participants, with a single Grade 3 or higher event reported, representing a notable reduction compared to prior intravenous or more frequent subcutaneous dosing methods. This reduction in high-grade ARRs signals an important step forward in minimizing treatment-related discomfort and adverse sequelae.

Common adverse events predominantly reflected the expected class effects of EGFR and MET pathway inhibition, including dermatologic manifestations such as paronychia and rash, as well as hypoalbuminemia. These toxicities were generally manageable and consistent with prior experience using these agents. Venous thromboembolic events (VTEs) appeared in 13% of patients but were limited to less severe grades, with no reports of Grade 3 or higher VTE complications, and bleeding events remained rare at a frequency of 1%, further cementing the regimen’s manageable safety profile.

Pharmacokinetic analysis revealed that mean plasma concentration levels of amivantamab with Q4W subcutaneous administration aligned closely with historical data from intravenous and every-two-week (Q2W) subcutaneous dosing schedules. This pharmacokinetic equivalence indicates that the prolonged dosing interval does not compromise drug exposure, adding mechanistic credence to the observed clinical efficacy and safety outcomes.

With just 8% of patients discontinuing therapy due to treatment-related adverse events, the Q4W administration regimen demonstrates not only clinical viability but also a meaningful enhancement of patient adherence potential—a critical factor in chronic cancer management. The subcutaneous route itself, compared to intravenous infusion, affords greater convenience for patients by reducing infusion chair time and associated resource utilization in outpatient oncology settings.

Dr. Susan Scott, leading investigator at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, emphasized that the trial’s data advocate for the incorporation of Q4W amivantamab dosing as a frontline strategy for EGFR-mutant NSCLC patients, underscoring that this less burdensome treatment model “offers a less burdensome treatment option without compromising efficacy.” According to her, the findings herald not only a therapeutic milestone but also a patient-centric evolution in lung cancer care, improving quality of life through simplified medication schedules.

This development is critically timely considering the ongoing global burden of lung cancer, as EGFR-driven NSCLC remains a prevalent and challenging disease entity with variable responses to targeted therapies. The flexibility and efficacy demonstrated by this subcutaneous Q4W dosing regimen open new horizons for therapeutic optimization and personalized cancer care paradigms.

The PALOMA-2 study’s positive outcomes resonate deeply within the research community, presenting an encouraging avenue for further exploration in subsequent phase trials and real-world clinical applications. The trial reinforces the growing consensus that targeted combinations leveraging antibody-based and kinase inhibitor modalities can deliver synergistic anticancer effects with manageable toxicity, a cornerstone principle in modern oncology innovation.

As the lung cancer field continues to evolve, the implications of these findings are profound: enabling effective control of tumor progression with improved patient experience may transform current treatment algorithms, particularly for the sizeable population of patients newly diagnosed with EGFR-mutant NSCLC, many of whom face rapidly advancing disease and complex clinical scenarios.

Looking ahead, longer-term follow-up and expanded patient cohorts will be essential to confirm the durability of response, overall survival benefits, and to further characterize the long-term safety profile of the Q4W amivantamab plus lazertinib combination. Still, the evidence amassed thus far provides a compelling rationale for healthcare providers to consider and advocate for subcutaneous amivantamab dosing strategies in future clinical practice guidelines.

In conclusion, the PALOMA-2 trial’s presentation at the 2025 WCLC stands as a landmark step forward in the quest to refine lung cancer therapeutics by integrating efficacy, convenience, and tolerability into new treatment paradigms that promise to improve outcomes for patients worldwide.

Subject of Research: Subcutaneous Amivantamab and Lazertinib Combination Therapy for Frontline Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Article Title: PALOMA-2 Trial Data Reveal Promising Efficacy and Safety of Once-Monthly Subcutaneous Amivantamab with Lazertinib in Untreated EGFR-Mutated NSCLC

News Publication Date: September 9, 2025

Web References: www.iaslc.org

Keywords: Lung cancer, NSCLC, EGFR mutation, amivantamab, lazertinib, targeted therapy, subcutaneous administration, PALOMA-2, clinical trial, EGFR Ex19del, L858R mutation, quality of life

The Phase I trial results, recently published in the esteemed journal Nature Medicine, revealed an extraordinary overall response rate of 92.9% with a complete response rate hitting 66.7%. These figures were derived from a cohort of 42 heavily pretreated patients, meaning they had undergone numerous prior therapies and were still persistent in their illness. Such promising statistics signal not only a potential new direction for treating refractory lymphomas but also the flexibility of this strategy to be adapted for broader types of cancer as research progresses.

Principal investigator Dr. Yago Nieto, who serves as a professor in the Stem Cell Transplantation & Cellular Therapy department at MD Anderson, articulated the significance of these findings. He underscores the rapid and potent responses observed in patients treated with the AFM13-NK cells, affirming the ongoing evaluations of the therapy’s effectiveness in tackling challenging malignancies. His enthusiasm points to a larger ambition that this therapeutic innovation may serve either as a curative measure for some patients or act as a crucial bridge to potentially life-saving stem cell transplants.

The methodology behind this trial hinges on the unique characteristics of Affimed’s AFM13 bispecific antibody. This engineered molecule is specifically designed to bind with CD16A on NK cells and detects CD30 on malignant lymphoma cells. With this pre-complexing approach, AFM13-NK cells are empowered to better target and obliterate CD30-positive lymphoma cells. The process involves initially activating the NK cells using cytokines, expanding them in conjunction with artificial antigen-presenting cells, and then combining them with the AFM13 antibody before infusing them into the patient’s bloodstream.

The laboratory contributions of Dr. Katy Rezvani, who holds the Sally Cooper Murray Endowed Chair in Cancer Research, are fundamental to the development of this cell therapy. As the vice president of the Institute for Cell Therapy Discovery & Innovation at MD Anderson, Dr. Rezvani has been pivotal in advancing cell therapies, highlighting a concerted effort towards developing impactful innovations for multiple medical conditions.

The trial specifically included 37 adult patients with known CD30-positive Hodgkin lymphoma and an additional five with T-cell lymphoma. Notably, all participants had been heavily pretreated and had demonstrated non-responsiveness to established therapies, such as brentuximab vedotin and the anti-PD1 immune checkpoint inhibitors. The trial participants had a median age of 43 years, with an alarming median of seven prior lines of treatment, showcasing the dire circumstances faced by these patients when entering the study.

The trial involved administering a series of two to four cycles of chemotherapy, subsequently followed by infusions of the AFM13-NK cells at three different dose levels across three weekly sessions. Each treatment cycle concluded with a rigorous evaluation of each participant’s treatment response on day 28, along with structured follow-ups every three months to monitor their ongoing health status.

The results were not just numeric; they painted a picture of hope. The overall response rate (ORR) and complete response (CR) rates among study participants stood at an impressive 92.9% and 66.7%, respectively. Among those diagnosed with Hodgkin lymphoma, the statistics climbed even higher, with ORR and CR reaching 97.3% and 73%. Such results, particularly when benchmarked against this heavily pretreated patient pool, underscore the noteworthy effectiveness of the AFM13-NK cell therapy in these challenging cases.

Over a median follow-up period of 20 months, the two-year event-free survival (EFS) and overall survival (OS) rates for participants were reported as 26.2% and 76.2%, respectively. Given the refractory nature of the tumors exhibited by participants, these survival rates are particularly encouraging, reinforcing the therapy’s potential impact on long-term patient outcomes.

Despite the complexity of the treatment, patients tolerated the AFM13-NK cell therapy well, with no documented instances of cytokine release syndrome, neurotoxicity associated with immune cells, or graft-versus-host disease, which are common complications in such treatments. The only adverse event noted was a Grade 2 infusion-related reaction, suggesting the treatment’s safety profile is remarkably favorable compared to other emerging therapies.

Cord blood units selected for each treatment cycle were sourced from the MD Anderson Cancer Center Cord Blood Bank, adhering to strict criteria established for optimal donor cell characteristics. This attention to donor cell quality ensured that NK cells reached peak levels in patient blood one day following infusion, with a notable persistence of healthy donor cells up to three weeks, effectively enabling them to migrate towards tumor sites.

In conclusion, the trial demonstrated a promising safety profile and an encouraging level of efficacy for AFM13-NK cells specifically in patients dealing with refractory CD30-positive Hodgkin lymphoma. Dr. Yago Nieto’s statement reflects a growing optimism about the potential applications of this cell therapy methodology, suggesting it could not only revolutionize treatment protocols for Hodgkin lymphoma but also lay the groundwork for future research involving NK cells used in conjunction with bispecific engagers for various malignancies.

The research was supported by Affimed, with additional funding from MD Anderson and contributions from the National Institutes of Health. With the trial continuing to gather insights and data, medical professionals remain hopeful about translating these findings into widespread clinical practice, ultimately enriching the therapeutic options available for patients battling difficult-to-treat cancers.

Subject of Research: Novel cell therapy using NK cells for refractory CD30-positive lymphomas
Article Title: Innovative Cell Therapy Offers Hope for Refractory CD30-Positive Lymphoma Patients
News Publication Date: [Not Provided]
Web References: [Not Provided]
References: [Not Provided]
Image Credits: [Not Provided]

Keywords: Natural killer cells, cancer patients, Hodgkin lymphoma, CD30, cell therapy, bispecific antibodies.